Raymond James Reiterates Outperform Rating on Compass Therapeutics (CMPX)

January 6, 2026 10:11 AM UTC Send to a Friend
Raymond James analyst Sean McCutcheon reiterated an Outperform rating and $9.00 price target on Compass Therapeutics (NASDAQ: CMPX).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login